![black female scientist fills vials](/sites/default/files/styles/445x610/public/media/images/black_female_scientist_fills_vials.jpg.webp?itok=TzBxb-qF)
Dihydropyrimidine dehydrogenase (DPD)
![black female scientist fills vials](/sites/default/files/styles/445x610/public/media/images/black_female_scientist_fills_vials.jpg.webp?itok=TzBxb-qF)
![light blue cells fused together](/sites/default/files/styles/fifty_fifty/public/media/images/light_blue_cells_fused.jpg.webp?itok=49De3Cn1)
What is a DPD biomarker?
Our bodies have a gene that produces the dihydropyrimidine dehydrogenase enzyme, which helps break down certain medications in the liver.
If there is mutation in the gene, your body will not produce enough of the dihydropyrimidine dehydrogenase enzyme. This condition is called dihydropyrimidine dehydrogenase deficiency (DPD).
Having DPD can cause fluorouracil-based chemotherapy drugs (which are commonly used in colon cancer treatment) to build up in your body and cause severely toxic reactions.
Note: It has been shown that pretreatment genetic testing for DPD may reveal a need to reduce fluoropyrimidine-based treatments (fluorouracil [FU], capecitabine, and other analogs) to avoid potential lethal toxicities.
![Latin woman smiling](/sites/default/files/styles/fifty_fifty/public/media/images/hispanic_woman_smiling.jpg.webp?itok=A13fzLJc)
Who should have DPD testing?
Because DPD mutations occur in less than 3% of the population, testing is usually not required unless a patient has an adverse reaction during treatment with fluorouracil-based chemotherapy drugs.
![woman in light blue scarf](/sites/default/files/styles/fifty_fifty/public/media/images/woman_in_blue_scarf.jpg.webp?itok=Edh9YN1Q)
What are the symptoms of low levels of DPD?
If you are experiencing side effects such as uncontrollable nausea, vomiting, or diarrhea, very low blood counts, high fevers, or extreme weakness during treatment with fluorouracil-based chemotherapy drugs, contact your doctor immediately.
Other biomarkers
HER2 / ERBB2 BiomarkerTop resources
![A sign at the BMS headquarters](/sites/default/files/styles/450x250/public/media/images/bms-sign-1920.png.webp?itok=qtRzhXHJ)
Krazati approved for previously treated KRASG12C colorectal cancer
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
![Christy Williams, a mom and colorectal cancer survivor, plays a table-top game with her family.](/sites/default/files/styles/450x250/public/media/images/christy-3.png.webp?itok=DxDhUqH-)
Christy Williams: Biomarker testing leads to successful treatment
Statistics suggested that Christy’s odds of survival were grim, so she leaned into her faith and kept a positive outlook. She tried to control what she could. And, critically, she received biomarker testing.
![Michelle Cappel: Biomarker testing extends life](/sites/default/files/styles/450x250/public/media/images/article/michelle-c-web.png.webp?itok=fV1oBKbJ)
Michelle Cappel: Biomarker testing extends life
Michelle Cappel owes a lot to colorectal cancer biomarker testing — seven years of life and counting.